Table of Content

1 Market Overview of Neoantigen Vaccine
1.1 Neoantigen Vaccine Market Overview
1.1.1 Neoantigen Vaccine Product Scope
1.1.2 Neoantigen Vaccine Market Status and Outlook
1.2 Global Neoantigen Vaccine Market Size Overview by Region 2024 VS 2022 VS 2034
1.3 Global Neoantigen Vaccine Market Size by Region (2024-2034)
1.4 Global Neoantigen Vaccine Historic Market Size by Region (2024-2024)
1.5 Global Neoantigen Vaccine Market Size Forecast by Region (2024-2034)
1.6 Key Regions, Neoantigen Vaccine Market Size (2024-2034)
1.6.1 North America Neoantigen Vaccine Market Size (2024-2034)
1.6.2 Europe Neoantigen Vaccine Market Size (2024-2034)
1.6.3 Asia-Pacific Neoantigen Vaccine Market Size (2024-2034)
1.6.4 Latin America Neoantigen Vaccine Market Size (2024-2034)
1.6.5 Middle East & Africa Neoantigen Vaccine Market Size (2024-2034)
2 Neoantigen Vaccine Market by Type
2.1 Introduction
2.1.1 Personalized Vaccine
2.1.2 Off-the shelf Vaccine
2.2 Global Neoantigen Vaccine Market Size by Type: 2024 VS 2022 VS 2034
2.2.1 Global Neoantigen Vaccine Historic Market Size by Type (2024-2024)
2.2.2 Global Neoantigen Vaccine Forecasted Market Size by Type (2024-2034)
2.3 Key Regions Market Size by Type
2.3.1 North America Neoantigen Vaccine Revenue Breakdown by Type (2024-2034)
2.3.2 Europe Neoantigen Vaccine Revenue Breakdown by Type (2024-2034)
2.3.3 Asia-Pacific Neoantigen Vaccine Revenue Breakdown by Type (2024-2034)
2.3.4 Latin America Neoantigen Vaccine Revenue Breakdown by Type (2024-2034)
2.3.5 Middle East and Africa Neoantigen Vaccine Revenue Breakdown by Type (2024-2034)
3 Neoantigen Vaccine Market Overview by Application
3.1 Introduction
3.1.1 Lung Cancer
3.1.2 Melanoma Cancer
3.1.3 Gastrointestinal Cancer
3.1.4 Brain Cancer
3.1.5 Others
3.2 Global Neoantigen Vaccine Market Size by Application: 2024 VS 2022 VS 2034
3.2.1 Global Neoantigen Vaccine Historic Market Size by Application (2024-2024)
3.2.2 Global Neoantigen Vaccine Forecasted Market Size by Application (2024-2034)
3.3 Key Regions Market Size by Application
3.3.1 North America Neoantigen Vaccine Revenue Breakdown by Application (2024-2034)
3.3.2 Europe Neoantigen Vaccine Revenue Breakdown by Application (2024-2034)
3.3.3 Asia-Pacific Neoantigen Vaccine Revenue Breakdown by Application (2024-2034)
3.3.4 Latin America Neoantigen Vaccine Revenue Breakdown by Application (2024-2034)
3.3.5 Middle East and Africa Neoantigen Vaccine Revenue Breakdown by Application (2024-2034)
4 Neoantigen Vaccine Competition Analysis by Players
4.1 Global Neoantigen Vaccine Market Size by Players (2024-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neoantigen Vaccine as of 2022)
4.3 Date of Key Players Enter into Neoantigen Vaccine Market
4.4 Global Top Players Neoantigen Vaccine Headquarters and Area Served
4.5 Key Players Neoantigen Vaccine Product Solution and Service
4.6 Competitive Status
4.6.1 Neoantigen Vaccine Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Neoantigen Vaccine Products, Services and Solutions
5.1.4 Pfizer Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.1.5 Pfizer Recent Developments
5.2 Merck & Co Inc
5.2.1 Merck & Co Inc Profile
5.2.2 Merck & Co Inc Main Business
5.2.3 Merck & Co Inc Neoantigen Vaccine Products, Services and Solutions
5.2.4 Merck & Co Inc Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.2.5 Merck & Co Inc Recent Developments
5.3 Eli Lilly and Company
5.3.1 Eli Lilly and Company Profile
5.3.2 Eli Lilly and Company Main Business
5.3.3 Eli Lilly and Company Neoantigen Vaccine Products, Services and Solutions
5.3.4 Eli Lilly and Company Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.3.5 BioNTech Recent Developments
5.4 BioNTech
5.4.1 BioNTech Profile
5.4.2 BioNTech Main Business
5.4.3 BioNTech Neoantigen Vaccine Products, Services and Solutions
5.4.4 BioNTech Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.4.5 BioNTech Recent Developments
5.5 Roche Holding AG
5.5.1 Roche Holding AG Profile
5.5.2 Roche Holding AG Main Business
5.5.3 Roche Holding AG Neoantigen Vaccine Products, Services and Solutions
5.5.4 Roche Holding AG Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.5.5 Roche Holding AG Recent Developments
5.6 OSE Immunotherapeutics
5.6.1 OSE Immunotherapeutics Profile
5.6.2 OSE Immunotherapeutics Main Business
5.6.3 OSE Immunotherapeutics Neoantigen Vaccine Products, Services and Solutions
5.6.4 OSE Immunotherapeutics Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.6.5 OSE Immunotherapeutics Recent Developments
5.7 Gritstone Bio
5.7.1 Gritstone Bio Profile
5.7.2 Gritstone Bio Main Business
5.7.3 Gritstone Bio Neoantigen Vaccine Products, Services and Solutions
5.7.4 Gritstone Bio Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.7.5 Gritstone Bio Recent Developments
5.8 Moderna
5.8.1 Moderna Profile
5.8.2 Moderna Main Business
5.8.3 Moderna Neoantigen Vaccine Products, Services and Solutions
5.8.4 Moderna Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.8.5 Moderna Recent Developments
5.9 Avidea Technologies
5.9.1 Avidea Technologies Profile
5.9.2 Avidea Technologies Main Business
5.9.3 Avidea Technologies Neoantigen Vaccine Products, Services and Solutions
5.9.4 Avidea Technologies Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.9.5 Avidea Technologies Recent Developments
5.10 Vaccibody AS
5.10.1 Vaccibody AS Profile
5.10.2 Vaccibody AS Main Business
5.10.3 Vaccibody AS Neoantigen Vaccine Products, Services and Solutions
5.10.4 Vaccibody AS Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.10.5 Vaccibody AS Recent Developments
5.11 Agenus Inc
5.11.1 Agenus Inc Profile
5.11.2 Agenus Inc Main Business
5.11.3 Agenus Inc Neoantigen Vaccine Products, Services and Solutions
5.11.4 Agenus Inc Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.11.5 Agenus Inc Recent Developments
5.12 Novogene
5.12.1 Novogene Profile
5.12.2 Novogene Main Business
5.12.3 Novogene Neoantigen Vaccine Products, Services and Solutions
5.12.4 Novogene Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.12.5 Novogene Recent Developments
5.13 ZIOPHARM Oncology
5.13.1 ZIOPHARM Oncology Profile
5.13.2 ZIOPHARM Oncology Main Business
5.13.3 ZIOPHARM Oncology Neoantigen Vaccine Products, Services and Solutions
5.13.4 ZIOPHARM Oncology Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.13.5 ZIOPHARM Oncology Recent Developments
5.14 ISA Pharmaceuticals
5.14.1 ISA Pharmaceuticals Profile
5.14.2 ISA Pharmaceuticals Main Business
5.14.3 ISA Pharmaceuticals Neoantigen Vaccine Products, Services and Solutions
5.14.4 ISA Pharmaceuticals Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.14.5 ISA Pharmaceuticals Recent Developments
5.15 BrightPath Biotherapeutics
5.15.1 BrightPath Biotherapeutics Profile
5.15.2 BrightPath Biotherapeutics Main Business
5.15.3 BrightPath Biotherapeutics Neoantigen Vaccine Products, Services and Solutions
5.15.4 BrightPath Biotherapeutics Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.15.5 BrightPath Biotherapeutics Recent Developments
5.16 Vaximm AG
5.16.1 Vaximm AG Profile
5.16.2 Vaximm AG Main Business
5.16.3 Vaximm AG Neoantigen Vaccine Products, Services and Solutions
5.16.4 Vaximm AG Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.16.5 Vaximm AG Recent Developments
5.17 Medigene AG
5.17.1 Medigene AG Profile
5.17.2 Medigene AG Main Business
5.17.3 Medigene AG Neoantigen Vaccine Products, Services and Solutions
5.17.4 Medigene AG Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.17.5 Medigene AG Recent Developments
5.18 Genocea Biosciences Inc
5.18.1 Genocea Biosciences Inc Profile
5.18.2 Genocea Biosciences Inc Main Business
5.18.3 Genocea Biosciences Inc Neoantigen Vaccine Products, Services and Solutions
5.18.4 Genocea Biosciences Inc Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.18.5 Genocea Biosciences Inc Recent Developments
5.19 Advaxis
5.19.1 Advaxis Profile
5.19.2 Advaxis Main Business
5.19.3 Advaxis Neoantigen Vaccine Products, Services and Solutions
5.19.4 Advaxis Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.19.5 Advaxis Recent Developments
5.20 Nouscom
5.20.1 Nouscom Profile
5.20.2 Nouscom Main Business
5.20.3 Nouscom Neoantigen Vaccine Products, Services and Solutions
5.20.4 Nouscom Neoantigen Vaccine Revenue (US$ Million) & (2024-2024)
5.20.5 Nouscom Recent Developments
6 North America
6.1 North America Neoantigen Vaccine Market Size by Country (2024-2034)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Neoantigen Vaccine Market Size by Country (2024-2034)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Neoantigen Vaccine Market Size by Region (2024-2034)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Neoantigen Vaccine Market Size by Country (2024-2034)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Neoantigen Vaccine Market Size by Country (2024-2034)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Neoantigen Vaccine Market Dynamics
11.1 Neoantigen Vaccine Industry Trends
11.2 Neoantigen Vaccine Market Drivers
11.3 Neoantigen Vaccine Market Challenges
11.4 Neoantigen Vaccine Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Neoantigen Vaccine Market Size (US$ Million) Comparison by Region 2024 VS 2022 VS 2034
Table 2. Global Neoantigen Vaccine Market Size by Region (2024-2024) & (US$ Million)
Table 3. Global Neoantigen Vaccine Market Size Share by Region (2024-2024)
Table 4. Global Neoantigen Vaccine Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 5. Global Neoantigen Vaccine Forecasted Market Size Share by Region (2024-2034)
Table 6. Global Neoantigen Vaccine Market Size (US$ Million) by Type: 2024 VS 2022 VS 2034
Table 7. Global Neoantigen Vaccine Market Size by Type (2024-2024) & (US$ Million)
Table 8. Global Neoantigen Vaccine Revenue Market Share by Type (2024-2024)
Table 9. Global Neoantigen Vaccine Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 10. Global Neoantigen Vaccine Revenue Market Share by Type (2024-2034)
Table 11. North America Neoantigen Vaccine Revenue by Type (2024-2024) & (US$ Million)
Table 12. North America Neoantigen Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 13. Europe Neoantigen Vaccine Revenue by Type (2024-2024) & (US$ Million)
Table 14. Europe Neoantigen Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 15. Asia-Pacific Neoantigen Vaccine Revenue by Type (2024-2024) & (US$ Million)
Table 16. Asia-Pacific Neoantigen Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 17. Latin America Neoantigen Vaccine Revenue by Type (2024-2024) & (US$ Million)
Table 18. Latin America Neoantigen Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 19. Middle East and Africa Neoantigen Vaccine Revenue by Type (2024-2024) & (US$ Million)
Table 20. Middle East and Africa Neoantigen Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 21. Global Neoantigen Vaccine Market Size (US$ Million) by Application: 2024 VS 2022 VS 2034
Table 22. Global Neoantigen Vaccine Market Size by Application (2024-2024) & (US$ Million)
Table 23. Global Neoantigen Vaccine Revenue Market Share by Application (2024-2024)
Table 24. Global Neoantigen Vaccine Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global Neoantigen Vaccine Revenue Market Share by Application (2024-2034)
Table 26. North America Neoantigen Vaccine Revenue by Application (2024-2024) & (US$ Million)
Table 27. North America Neoantigen Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 28. Europe Neoantigen Vaccine Revenue by Application (2024-2024) & (US$ Million)
Table 29. Europe Neoantigen Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 30. Asia-Pacific Neoantigen Vaccine Revenue by Application (2024-2024) & (US$ Million)
Table 31. Asia-Pacific Neoantigen Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 32. Latin America Neoantigen Vaccine Revenue by Application (2024-2024) & (US$ Million)
Table 33. Latin America Neoantigen Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 34. Middle East and Africa Neoantigen Vaccine Revenue by Application (2024-2024) & (US$ Million)
Table 35. Middle East and Africa Neoantigen Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 36. Global Neoantigen Vaccine Revenue (US$ Million) by Players (2024-2024)
Table 37. Global Neoantigen Vaccine Revenue Market Share by Players (2024-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neoantigen Vaccine as of 2022)
Table 39. Date of Key Players Enter into Neoantigen Vaccine Market
Table 40. Global Neoantigen Vaccine Key Players Headquarters and Area Served
Table 41. Neoantigen Vaccine Product Solution and Service
Table 42. Global Neoantigen Vaccine Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Pfizer Basic Information List
Table 45. Pfizer Description and Business Overview
Table 46. Pfizer Neoantigen Vaccine Products, Services and Solutions
Table 47. Revenue (US$ Million) in Neoantigen Vaccine Business of Pfizer (2024-2024)
Table 48. Pfizer Recent Developments
Table 49. Merck & Co Inc Basic Information List
Table 50. Merck & Co Inc Description and Business Overview
Table 51. Merck & Co Inc Neoantigen Vaccine Products, Services and Solutions
Table 52. Revenue (US$ Million) in Neoantigen Vaccine Business of Merck & Co Inc (2024-2024)
Table 53. Merck & Co Inc Recent Developments
Table 54. Eli Lilly and Company Basic Information List
Table 55. Eli Lilly and Company Description and Business Overview
Table 56. Eli Lilly and Company Neoantigen Vaccine Products, Services and Solutions
Table 57. Revenue (US$ Million) in Neoantigen Vaccine Business of Eli Lilly and Company (2024-2024)
Table 58. Eli Lilly and Company Recent Developments
Table 59. BioNTech Basic Information List
Table 60. BioNTech Description and Business Overview
Table 61. BioNTech Neoantigen Vaccine Products, Services and Solutions
Table 62. Revenue (US$ Million) in Neoantigen Vaccine Business of BioNTech (2024-2024)
Table 63. BioNTech Recent Developments
Table 64. Roche Holding AG Basic Information List
Table 65. Roche Holding AG Description and Business Overview
Table 66. Roche Holding AG Neoantigen Vaccine Products, Services and Solutions
Table 67. Revenue (US$ Million) in Neoantigen Vaccine Business of Roche Holding AG (2024-2024)
Table 68. Roche Holding AG Recent Developments
Table 69. OSE Immunotherapeutics Basic Information List
Table 70. OSE Immunotherapeutics Description and Business Overview
Table 71. OSE Immunotherapeutics Neoantigen Vaccine Products, Services and Solutions
Table 72. Revenue (US$ Million) in Neoantigen Vaccine Business of OSE Immunotherapeutics (2024-2024)
Table 73. OSE Immunotherapeutics Recent Developments
Table 74. Gritstone Bio Basic Information List
Table 75. Gritstone Bio Description and Business Overview
Table 76. Gritstone Bio Neoantigen Vaccine Products, Services and Solutions
Table 77. Revenue (US$ Million) in Neoantigen Vaccine Business of Gritstone Bio (2024-2024)
Table 78. Gritstone Bio Recent Developments
Table 79. Moderna Basic Information List
Table 80. Moderna Description and Business Overview
Table 81. Moderna Neoantigen Vaccine Products, Services and Solutions
Table 82. Revenue (US$ Million) in Neoantigen Vaccine Business of Moderna (2024-2024)
Table 83. Moderna Recent Developments
Table 84. Avidea Technologies Basic Information List
Table 85. Avidea Technologies Description and Business Overview
Table 86. Avidea Technologies Neoantigen Vaccine Products, Services and Solutions
Table 87. Revenue (US$ Million) in Neoantigen Vaccine Business of Avidea Technologies (2024-2024)
Table 88. Avidea Technologies Recent Developments
Table 89. Vaccibody AS Basic Information List
Table 90. Vaccibody AS Description and Business Overview
Table 91. Vaccibody AS Neoantigen Vaccine Products, Services and Solutions
Table 92. Revenue (US$ Million) in Neoantigen Vaccine Business of Vaccibody AS (2024-2024)
Table 93. Vaccibody AS Recent Developments
Table 94. Agenus Inc Basic Information List
Table 95. Agenus Inc Description and Business Overview
Table 96. Agenus Inc Neoantigen Vaccine Products, Services and Solutions
Table 97. Revenue (US$ Million) in Neoantigen Vaccine Business of Agenus Inc (2024-2024)
Table 98. Agenus Inc Recent Developments
Table 99. Novogene Basic Information List
Table 100. Novogene Description and Business Overview
Table 101. Novogene Neoantigen Vaccine Products, Services and Solutions
Table 102. Revenue (US$ Million) in Neoantigen Vaccine Business of Novogene (2024-2024)
Table 103. Novogene Recent Developments
Table 104. ZIOPHARM Oncology Basic Information List
Table 105. ZIOPHARM Oncology Description and Business Overview
Table 106. ZIOPHARM Oncology Neoantigen Vaccine Products, Services and Solutions
Table 107. Revenue (US$ Million) in Neoantigen Vaccine Business of ZIOPHARM Oncology (2024-2024)
Table 108. ZIOPHARM Oncology Recent Developments
Table 109. ISA Pharmaceuticals Basic Information List
Table 110. ISA Pharmaceuticals Description and Business Overview
Table 111. ISA Pharmaceuticals Neoantigen Vaccine Products, Services and Solutions
Table 112. Revenue (US$ Million) in Neoantigen Vaccine Business of ISA Pharmaceuticals (2024-2024)
Table 113. ISA Pharmaceuticals Recent Developments
Table 114. BrightPath Biotherapeutics Basic Information List
Table 115. BrightPath Biotherapeutics Description and Business Overview
Table 116. BrightPath Biotherapeutics Neoantigen Vaccine Products, Services and Solutions
Table 117. Revenue (US$ Million) in Neoantigen Vaccine Business of BrightPath Biotherapeutics (2024-2024)
Table 118. BrightPath Biotherapeutics Recent Developments
Table 119. Vaximm AG Basic Information List
Table 120. Vaximm AG Description and Business Overview
Table 121. Vaximm AG Neoantigen Vaccine Products, Services and Solutions
Table 122. Revenue (US$ Million) in Neoantigen Vaccine Business of Vaximm AG (2024-2024)
Table 123. Vaximm AG Recent Developments
Table 124. Medigene AG Basic Information List
Table 125. Medigene AG Description and Business Overview
Table 126. Medigene AG Neoantigen Vaccine Products, Services and Solutions
Table 127. Revenue (US$ Million) in Neoantigen Vaccine Business of Medigene AG (2024-2024)
Table 128. Medigene AG Recent Developments
Table 129. Genocea Biosciences Inc Basic Information List
Table 130. Genocea Biosciences Inc Description and Business Overview
Table 131. Genocea Biosciences Inc Neoantigen Vaccine Products, Services and Solutions
Table 132. Revenue (US$ Million) in Neoantigen Vaccine Business of Genocea Biosciences Inc (2024-2024)
Table 133. Genocea Biosciences Inc Recent Developments
Table 134. Advaxis Basic Information List
Table 135. Advaxis Description and Business Overview
Table 136. Advaxis Neoantigen Vaccine Products, Services and Solutions
Table 137. Revenue (US$ Million) in Neoantigen Vaccine Business of Advaxis (2024-2024)
Table 138. Advaxis Recent Developments
Table 139. Nouscom Basic Information List
Table 140. Nouscom Description and Business Overview
Table 141. Nouscom Neoantigen Vaccine Products, Services and Solutions
Table 142. Revenue (US$ Million) in Neoantigen Vaccine Business of Nouscom (2024-2024)
Table 143. Nouscom Recent Developments
Table 144. North America Neoantigen Vaccine Market Size by Country (2024-2024) & (US$ Million)
Table 145. North America Neoantigen Vaccine Market Size by Country (2024-2034) & (US$ Million)
Table 146. Europe Neoantigen Vaccine Market Size by Country (2024-2024) & (US$ Million)
Table 147. Europe Neoantigen Vaccine Market Size by Country (2024-2034) & (US$ Million)
Table 148. Asia-Pacific Neoantigen Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 149. Asia-Pacific Neoantigen Vaccine Market Size by Region (2024-2024) & (US$ Million)
Table 150. Asia-Pacific Neoantigen Vaccine Market Size by Region (2024-2034) & (US$ Million)
Table 151. Asia-Pacific Neoantigen Vaccine Market Share by Region (2024-2024)
Table 152. Asia-Pacific Neoantigen Vaccine Market Share by Region (2024-2034)
Table 153. Latin America Neoantigen Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 154. Latin America Neoantigen Vaccine Market Size by Country (2024-2024) & (US$ Million)
Table 155. Latin America Neoantigen Vaccine Market Size by Country (2024-2034) & (US$ Million)
Table 156. Middle East & Africa Neoantigen Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 157. Middle East & Africa Neoantigen Vaccine Market Size by Country (2024-2024) & (US$ Million)
Table 158. Middle East & Africa Neoantigen Vaccine Market Size by Country (2024-2034) & (US$ Million)
Table 159. Neoantigen Vaccine Market Trends
Table 160. Neoantigen Vaccine Market Drivers
Table 161. Neoantigen Vaccine Market Challenges
Table 162. Neoantigen Vaccine Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neoantigen Vaccine Market Size Year-over-Year 2024-2034 & (US$ Million)
Figure 2. Global Neoantigen Vaccine Market Size (US$ Million), 2024 VS 2022 VS 2034
Figure 3. Global Neoantigen Vaccine Market Share by Regions: 2022 VS 2034
Figure 4. Global Neoantigen Vaccine Forecasted Market Size Share by Region (2024-2034)
Figure 5. North America Neoantigen Vaccine Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 6. Europe Neoantigen Vaccine Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 7. Asia-Pacific Neoantigen Vaccine Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 8. Latin America Neoantigen Vaccine Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 9. Middle East & Africa Neoantigen Vaccine Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 10. Product Picture of Personalized Vaccine
Figure 11. Global Personalized Vaccine Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 12. Product Picture of Off-the shelf Vaccine
Figure 13. Global Off-the shelf Vaccine Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 14. Global Neoantigen Vaccine Market Size Share by Type: 2022 & 2034
Figure 15. North America Neoantigen Vaccine Revenue Market Share by Type (2024-2034)
Figure 16. Europe Neoantigen Vaccine Revenue Market Share by Type (2024-2034)
Figure 17. Asia-Pacific Neoantigen Vaccine Revenue Market Share by Type (2024-2034)
Figure 18. Latin America Neoantigen Vaccine Revenue Market Share by Type (2024-2034)
Figure 19. Middle East and Africa Neoantigen Vaccine Revenue Market Share by Type (2024-2034)
Figure 20. Lung Cancer Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 21. Melanoma Cancer Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 22. Gastrointestinal Cancer Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 23. Brain Cancer Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 24. Others Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 25. Global Neoantigen Vaccine Market Size Share by Application: 2022 & 2034
Figure 26. North America Neoantigen Vaccine Revenue Market Share by Application (2024-2034)
Figure 27. Europe Neoantigen Vaccine Revenue Market Share by Application (2024-2034)
Figure 28. Asia-Pacific Neoantigen Vaccine Revenue Market Share by Application (2024-2034)
Figure 29. Latin America Neoantigen Vaccine Revenue Market Share by Application (2024-2034)
Figure 30. Middle East and Africa Neoantigen Vaccine Revenue Market Share by Application (2024-2034)
Figure 31. Neoantigen Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 32. Global Top 5 and Top 10 Players Neoantigen Vaccine Market Share in 2022
Figure 33. North America Neoantigen Vaccine Market Share by Country (2024-2034)
Figure 34. United States Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 35. Canada Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 36. Germany Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 37. France Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 38. U.K. Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 39. Italy Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 40. Russia Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 41. Nordic Countries Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 42. Asia-Pacific Neoantigen Vaccine Market Share by Region (2024-2034)
Figure 43. China Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 44. Japan Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 45. South Korea Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 46. Southeast Asia Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 47. India Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 48. Australia Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 49. Latin America Neoantigen Vaccine Market Share by Country (2024-2034)
Figure 50. Mexico Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 51. Brazil Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 52. Middle East & Africa Neoantigen Vaccine Market Share by Country (2024-2034)
Figure 53. Turkey Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 54. Saudi Arabia Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 55. UAE Neoantigen Vaccine Market Size (2024-2034) & (US$ Million)
Figure 56. Bottom-up and Top-down Approaches for This Report